Video

Dr. Hammers on the Potential Utility of HIF-2α Inhibitors in RCC

Hans Hammers, MD, PhD, discusses the potential utility of HIF-2α inhibitors in renal cell carcinoma.

Hans Hammers, MD, PhD, an associate professor of internal medicine in the Division of Hematology-Oncology at The University of Texas Southwestern Medical Center, discusses the potential utility of HIF-2α inhibitors in renal cell carcinoma (RCC).

HIF-2α inhibitors are emerging agents that could transform the treatment paradigm of RCC, says Hammers. One compound called belzutifan (MK-6482) has demonstrated significant potential in this setting, Hammers explains.

According to updated findings from a phase 1/2 study (NCT02974738), belzutifan induced an overall response rate of 25% and a disease control rate of 80% in patients with advanced clear cell RCC. Regarding safety, anemia and hypoxia were the most commonly reported grade 3 adverse effects, concludes Hammers.

Related Videos
Dingwei Ye, MD, PhD
Areej El-Jawahri, MD, associate director, Cancer Outcomes Research and Education Program, director, Bone Marrow Transplant Survivorship Program, associate professor, medicine, Massachusetts General Hospital
Sandy Srinivas, MD
David Rimm, MD, PhD
Angeles A. Secord, MD, MHSc
Alexandra Drakaki, MD, PhD
Idoroenyi Amanam, MD
Sagar Lonial, MD, FACP
Leo I. Gordon, MD
Andrea Wolf, MD, MPH